We read that the FDA is listing Novo drugs as 'available', dismissed

Rise and shine, everyone, another busy day is coming. We can tell by the sudden presence of little ghosts and goblins walking by. They are undoubtedly looking for the big pumpkin. We wish them the best of luck, because you never know what you’ll encounter on that elusive quest. Of course, that requires a bowl of stimulation and that’s why we’re opening a new package of pecan pie for the occasion. What awaits us now, however, is our ever-growing to-do list. Sound familiar? So here are some interesting items. Have a nice day everyone. …

All doses of Novo Nordisk’s successful diabetes and obesity treatments are listed as available has been on the U.S. Food and Drug Administration’s drug shortage list since Wednesdayraising the possibility that the drugs could soon be completely delisted, a development that could impact compounding pharmacies and patients dependent on compounded medications, STAT reports. Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for more than two years, with different doses listed in shortages at different times. Now that all doses are available, the FDA could soon delist the drug, depending on discussions with Novo about whether the company can adequately meet demand in the future.

Layoffs in the US pharmaceutical industry fell last month, although job losses are still well above levels seen during the same period in 2023. according to Challenger, Gray & Christmas, the outplacement and executive coaching firm. A total of 424 jobs were cut in October, far below the 3,073 jobs cut in September. This was also well below the 1,624 jobs the sector cut in October 2023. So far this year, pharmaceutical companies have cut a total of 12,751 jobs, which is more than the 10,025 jobs cut at the same time in 2023.

STAT+ Exclusive story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article – plus in-depth analysis, newsletters, premium events and news alerts.

Do you already have an account? Login

View all subscriptions

Subscribe to STAT+ to read the rest of this story.